• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz . Seroprevalence of SARS-CoV-2 among children and adolescents in Germany-an overview

tetano

Editor, Senior Moderator
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz


. 2021 Nov 3.
doi: 10.1007/s00103-021-03448-0. Online ahead of print.
[Seroprevalence of SARS-CoV-2 among children and adolescents in Germany-an overview]


[Article in German]

Roma Thamm[SUP] 1 [/SUP], Nina Buttmann-Schweiger[SUP] 2 [/SUP], Julia Fiebig[SUP] 2 [/SUP], Christina Poethko-Müller[SUP] 2 [/SUP], Franziska Prütz[SUP] 2 [/SUP], Giselle Sarganas[SUP] 2 [/SUP], Hannelore Neuhauser[SUP] 2 [/SUP]



Affiliations

Abstract

in English, German
Background: SARS-CoV‑2 serologic studies complement and expand findings from confirmed COVID-19 cases through identification of undetected cases.
Objectives: This article summarizes previous results on SARS-CoV‑2 prevalence from seroepidemiological studies in Germany focusing on children and adolescents and complements the already existing overview on seroprevalence in adults from general population samples and especially blood donors in Germany.
Methods: The results are based on an ongoing systematic search in study registries, in literature databases, of preprint publications, and of media reports of seroepidemiological studies in Germany and their results.
Results: As of 17 September 2021, we are aware of 16 German seroepidemiological studies focusing on children and adolescents. Results are available for nine of these studies. For almost all settings studied, SARS-CoV‑2 seroprevalence was well below 1% for preschool and elementary school children in the first COVID-19 wave and below 2% for adolescents. As the pandemic progressed, higher seroprevalences of up to 8% were found in elementary school children.
Discussion: Results of SARS-CoV‑2 antibody studies in children and adolescents in Germany are scarce so far and are based on non-representative samples at local or regional level. In future studies, it is necessary on the one hand to estimate which proportion of children and adolescents has already either had an infection or has been vaccinated. On the other hand, it is important to investigate physical and mental health impairments that occur after an infection.

Keywords: Antibodies; Children and adolescents; Coronavirus; Immunity; Serology.
 
Back
Top Bottom